Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
- Oncospecials15m 30s
A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais
ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.oncologia ccr câncer renal tki sunitinibe - Myelodysplastic Syndromes23m 43s
Desenvolvimento e Atualizações na Biologia das Mielodisplasias
Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)síndromes mielodisplásicas mds avanços na biologia terapias inovadoras epidemiologia da mds - Mieloma múltiplo7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.minimum residual disease (mrd) mrd negativity multiple myeloma - Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromeslow risk mds venetoclax viale -a eln classification low dose lenalidomide tags: azacitidine - Mieloma múltiplo9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.pomalidomide-dexamethasone rrmm management progression-free survival combination therapies - Transplant15m 53s
Profilaxia de CMV em receptores de transplantes
Conheça as estratégias de profilaxia de CMV no pós-transplante de órgãos sólidos, melhor forma de manejo e monitorização de viremia.cmv hospitalar valganciclovir antiviral manejo de viremia transplante - Câncer de próstata6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPCnmcrpc metastasis free survival spartan prosper & aramis clinical trial - nasopharyngeal carcinoma44m 35s
Comprehensive Overview of Nasopharyngeal Carcinoma
Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.nasopharyngeal carcinoma immunotherapy - 3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.her2 positive mbc prolonged remission trastuzumab duration - 3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.her2 positive mbc prolonged remission trastuzumab duration
- 1
A Relevância dos Agentes TKI na era das...
- 2
Desenvolvimento e Atualizações na Biologia das...
- 3
MRD Assesment in Multiple Myeloma -Ready for Prime...
- 4
ASH 2022 Update on Myelodysplastic Syndromes
- 5
Integrating Pomalidomide Based Regimens in Multiple...
- 6
Profilaxia de CMV em receptores de transplantes
- 7
Managing Nonmetastatic Castration-Resistant...
- 8
Comprehensive Overview of Nasopharyngeal Carcinoma
- 9
Duration of trastuzumab in patients with Her2...
- 10
Duration of trastuzumab in patients with Her2...